peptide and neuropeptide  WHAT'S NEW
 peptide and neuropeptide  ONLINE CATALOG
 peptide and neuropeptide  CUSTOM SYNTHESIS
 peptide and neuropeptide  ANALYTICAL DATA SHEET (ADS)
 peptide and neuropeptide  SERVICES
 peptide and neuropeptide  TECHNICAL LIBRARY
 peptide and neuropeptide  DOCUMENTS
 peptide and neuropeptide  SITEMAP
 peptide and neuropeptide  JOBS
 peptide and neuropeptide  CONTACT
   BOOKMARK & SHARE
  © Bachem Holding AG
peptides


Bachem - # 1 in Peptides

peptide, peptides, neuropeptide, neuropeptides and biochemicals

peptide and neuropeptide peptide
Glucagon
# 1 in large scale GMP Peptide Production
more biochemicals
peptide and neuropeptide
# 1 in Regulatory Support
more peptide and neuropeptide
peptide and neuropeptide
# 1 in Custom Peptides Expertise
more peptide and neuropeptide
peptide and neuropeptide
# 1 comprehensive Catalog
more peptide and neuropeptide



Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.


Breaking News:


July 28, 2010

Save 50% on selected Amino Acid Derivatives and Loaded Resins for Fmoc- and Boc-SPPS
Check out the complete list of heavily discounted products.

special offers


July 14, 2010

10 new products have been added to the online catalog today.
Check out the complete list of additions.

new products


June 17, 2010

Bachem sells stake in Polyphor to Ingro Finanz AG
Bachem today announced that the company on June 16, 2010, has sold its complete stake in Polyphor AG to Ingro Finanz AG. The involved parties have agreed not to disclose the purchase price in the transaction.

peptidePress ReleasepeptidesPressemitteilung


June 2, 2010

Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP for phase III clinical trials
Bachem and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of finished dosage forms of ISA Pharmaceutical's immunotherapeutic HPV-SLP product.

peptidePress ReleasepeptidesPressemitteilung


To view all breaking news, go to the archive


Easy Ordering Home